BioSpace News Archive

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre (“Bloom”), a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments.

Researchers from the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia (CHOP) have developed an algorithm that uses existing electronic health records to distinguish patients with attention-deficit/hyperactivity disorder (ADHD).

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC), a global provider of financial services and healthcare software and software-enabled services, will announce its financial results for second quarter ended June 30, 2022 after the close of the market on Wednesday, July 27, 2022.

Infor®, the industry cloud company, today announced a new partnership with Syntellis™ Performance Solutions, the leading provider of enterprise performance management (EPM) software, data and intelligence solutions.

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a health technology company, today announced that it has appointed Allison Blackwell as Chief Human Resources Officer, effective immediately.

Lexaria Bioscience Corp. announces the pending start of its upcoming human nicotine study NIC-H22-1.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022.

Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the enrollment of the first patient in its Canadian prospective, post-market, observational study to further demonstrate the benefits of SCOUT, a wireless, radar-guided localization system used to assist breast surgeons in identifying biopsied tumors for removal during breast-conserving surgery.

MM is a highly challenging and deadly blood cancer that forms in plasma cells, a type of white blood cell.